Skip to main content

Active Motif Recombinant COVID-19 Antibodies

Active Motif said that in February it successfully isolated antibodies from patients in China recovering from COVID-19, and that the full suite of antibodies is now available for research applications and diagnostic test development. In collaboration with Fudan University and its Public Health Clinical Center, the company used its proprietary single-cell AbEpic screening technology to isolate the antibodies from patients, whose samples were screened to obtain whole human IgG antibody clones that have been sequenced, expressed, and characterized for binding directly to the SARS-CoV-2 S1 protein.